Reduction in oropharyngeal candidiasis following introduction of protease inhibitors.
Hood
S
S
Bonington
A
A
Evans
J
J
Denning
D
D
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D000935:Antifungal Agents; D017320:HIV Protease Inhibitors; D015725:Fluconazole